Anzeige
Meldung des Tages: Der Countdown zu einer der heißesten AI-Hightech-Stories 2026 beginnt jetzt

Ipsen Aktie News

Aktie
WKN:  A0ESMG ISIN:  FR0010259150 US-Symbol:  IPSEF Branche:  Pharmazeutika Land:  Frankreich
136,20 €
-1,10 €
-0,80%
08:01:26 Uhr
Depot/Watchlist
Marktkapitalisierung *
10,01 Mrd. €
Streubesitz
27,41%
KGV
26,60
Dividende
1,40 €
Dividendenrendite
1,18%
neu: Nachhaltigkeits-Score
68 %
Index-Zuordnung
-

Ipsen News

29.01.26 - GlobeNewswire
Ipsen nominates Peter Guenter to its Board of Directors
PARIS, FRANCE, 29 January 2026  - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-​optation of Peter Guenter to its Board as a Director, effective January 28, 2026, ...
27.01.26 - GlobeNewswire
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
PARIS, FRANCE, 27 January 2026  - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of ...
21.01.26 - GlobeNewswire
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026  – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final ...
14.01.26 - GlobeNewswire
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disorders Interim ...
13.01.26 - GlobeNewswire
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, ...
22.12.25 - GlobeNewswire
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-​drug conjugate ...
19.12.25 - GlobeNewswire
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025  - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new ...
15.12.25 - GlobeNewswire
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025  – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French ...
01.12.25 - GlobeNewswire
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
PARIS, FRANCE, 1 DECEMBER 2025 - It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a ...
07.11.25 - GlobeNewswire
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and ...
22.10.25 - GlobeNewswire
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Year-​to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and ...
22.10.25 - GlobeNewswire
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Acquisition focused on lead clinical-​stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 ...
22.09.25 - GlobeNewswire
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
IPN10200 is a recombinant, first-​in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, ...
19.09.25 - GlobeNewswire
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Bylvay ® is the first once-​daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in ...
31.07.25 - GlobeNewswire
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
H1 total sales growth of 11.4% at CER 1 , or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core ...
24.07.25 - GlobeNewswire
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of ...
23.07.25 - GlobeNewswire
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive ...
20.06.25 - GlobeNewswire
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade ...
31.05.25 - GlobeNewswire
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study ...
07.05.25 - GlobeNewswire
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
Additional late-​breaking data suggests up to twice as many patients treated with IQIRVO ® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 ...

Newssuche

Videos

newspaper
29.01.26 -3,53%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »